159 related articles for article (PubMed ID: 16109603)
1. Clinical implications of blast immunophenotypes in myelodysplastic syndromes.
Ogata K; Yoshida Y
Leuk Lymphoma; 2005 Sep; 46(9):1269-74. PubMed ID: 16109603
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome.
Ogata K; Nakamura K; Yokose N; Tamura H; Tachibana M; Taniguchi O; Iwakiri R; Hayashi T; Sakamaki H; Murai Y; Tohyama K; Tomoyasu S; Nonaka Y; Mori M; Dan K; Yoshida Y
Blood; 2002 Dec; 100(12):3887-96. PubMed ID: 12393641
[TBL] [Abstract][Full Text] [Related]
3. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
Xie W; Wang X; Du W; Liu W; Qin X; Huang S
Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
[TBL] [Abstract][Full Text] [Related]
4. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
5. [Four-color flow cytometric immunophenotypic features of blasts in myelodysplastic syndromes].
Wu YJ; Li JY; Qiu HR; Xiao B; Zhang JF; Song JH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):50-3. PubMed ID: 16584591
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of immunophenotypic features of blasts in patients with myelodysplastic syndrome by flow cytometry and its diagnostic significance].
Sun JF; Yang B; Zhang L; Huang Y; Yang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):632-5. PubMed ID: 22739171
[TBL] [Abstract][Full Text] [Related]
7. Myeloblasts transition to megakaryoblastic immunophenotypes over time in some patients with myelodysplastic syndromes.
Ogata K; Mochimaru Y; Sei K; Kawahara N; Ogata M; Yamamoto Y
PLoS One; 2023; 18(9):e0291662. PubMed ID: 37729123
[TBL] [Abstract][Full Text] [Related]
8. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
[TBL] [Abstract][Full Text] [Related]
9. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
10. Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells.
Sawada K; Sato N; Notoya A; Tarumi T; Hirayama S; Takano H; Koizumi K; Yasukouchi T; Yamaguchi M; Koike T
Blood; 1995 Jan; 85(1):194-202. PubMed ID: 7528567
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotype of myeloid granulocytes: a pilot study for distinguishing myelodysplastic syndrome and aplastic anemia by flow cytometry.
Huang M; Li J; Zhao G; Sui X; Zhao X; Xu H
Int J Lab Hematol; 2010 Jun; 32(3):275-81. PubMed ID: 19968721
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
[TBL] [Abstract][Full Text] [Related]
13. [Study on the immunophenotypes of bone marrow cells from patients with myelodysplastic syndromes and its clinical implications].
Wang JY; Li XM; Li FJ; Chen XG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Apr; 10(2):173-4. PubMed ID: 12513825
[TBL] [Abstract][Full Text] [Related]
14. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic significance of immunophenotyping of bone marrow cells in myelodysplastic syndrome without an increase of marrow blasts].
Xu J; Zhang W; Liu Y; Wan SG; Sun XJ; Zhao H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1477-81. PubMed ID: 20030930
[TBL] [Abstract][Full Text] [Related]
17. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
[TBL] [Abstract][Full Text] [Related]
18. Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes.
Ogata K; Satoh C; Hyodo H; Tamura H; Dan K; Yoshida Y
Leuk Res; 2004 Nov; 28(11):1171-5. PubMed ID: 15380341
[TBL] [Abstract][Full Text] [Related]
19. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic clustering of myelodysplastic syndromes.
Maynadié M; Picard F; Husson B; Chatelain B; Cornet Y; Le Roux G; Campos L; Dromelet A; Lepelley P; Jouault H; Imbert M; Rosenwadj M; Vergé V; Bissières P; Raphaël M; Béné MC; Feuillard J;
Blood; 2002 Oct; 100(7):2349-56. PubMed ID: 12239142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
